Ongoing clinical trials with PARPi [ABT-888], either as a single agent or in combination therapy, aim to identify suitable patients for PARPi sensitivity, beside BRCA mutations, that show HR or MMR deficiency (NCT01237067, NCT02660034, NCT02576444, NCT02286687, NCT01891344, NCT02354131) by measuring γH2AX and FANCD2 foci formation in FFPE tumor samples [167, 172, 177] (NCT01017640; NCT01251874). This evidence concerns the gene FANCD2 and neoplasm.